-transparent.png){kind=logo}
Prostate-specific Membrane Antigen PET in Prostate Cancer. 2021
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
From the Department of Radiology and Biomedical Imaging (C.L.H., S.C.B., T.A.H.) and Helen Diller Family Comprehensive Cancer Center (S.C.B., T.A.H.), University of California San Francisco, 505 Parnassus Ave, M391, San Francisco, CA 94143; Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Md (A.S., S.P.R.); Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (J.C.); Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (W.P.F.); Department of Nuclear Medicine, Technical University of Munich, Munich, Germany (M.E.); Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia (L.E.); Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.
Related Publications
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
May 2018,
Current opinion in oncology,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
September 2022,
Radiology,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
November 2016,
Future oncology (London, England),
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
January 2013,
Current topics in medicinal chemistry,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
September 2020,
Current opinion in urology,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
September 2020,
Current opinion in urology,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
January 2020,
Radiographics : a review publication of the Radiological Society of North America, Inc,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
January 2018,
Korean journal of radiology,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
June 2018,
Clinical nuclear medicine,
Courtney Lawhn-Heath, and
Ali Salavati, and
Spencer C Behr, and
Steven P Rowe, and
Jeremie Calais, and
Wolfgang P Fendler, and
Mattias Eiber, and
Louise Emmett, and
Michael S Hofman, and
Thomas A Hope
September 2020,
Clinical nuclear medicine,
